Interleukin 2 (IL-2) directly affects the function of both neurons and glia in the nervous system. It can induce proliferation and differentiation or cause cell death in oligodendrocytes. We have previously cloned the cDNAs for the alpha (a), beta (b), and gamma (g) chains of the IL-2 receptor (IL-2R) complex from a human oligodendroglioma cell line TC620. In an effort to characterize the IL-2 receptor (IL-2R) on oligodendrocytes, experiments were performed using recombinant human IL-2 on normal human oligodendrocytes from adult brain tissue and the IL-2-responsive subclone TC620.6A2 of the oligodendroglioma line. The TC620 subclone has the phenotype of an immature oligodendrocyte. At 5 nM IL-2, there was a 2.5-fold increase in proliferation of both normal and malignant human oligodendrocytes. This response was receptor-mediated in that binding of 125 I-IL-2 to TC620.6A2 cells detected a single receptor class for IL-2 with an affinity of 3.6 nM. Immunohistochemical staining of TC620.6A2 cells with a panel of monoclonal antibodies to different epitopes of the human IL-2Ra chain demonstrated the presence of IL-2Ra on the surface of these cells, in staining patterns which did not always coincide with those found on T cells. Neither the b nor the g chain of the IL-2R complex was detected on human oligodendrocytes by immunohistochemistry. Those antibodies which recognized cell surface IL-2Ra epitopes on TC620.6A2 blocked IL-2-induced proliferation, while those which did not detect cell surface IL-2Ra epitopes were not inhibitory. This same panel of monoclonal antibodies, when used to probe membrane preparations of TC620.6A2 cells on a Western blot, detected three proteins of 100, 83, and 47 kDa, in contrast to the 55-kDa IL-2Ra observed on T cells. ᭧ 1997 Academic Press
INTRODUCTION
Interleukin 2 (IL-2), initially characterized as an important element in immune responsiveness, is now recognized as being able to affect cells of the central nervous system (CNS) as well. In addition to the proliferative and differentiative effects IL-2 has on glial cells (reviewed in Benveniste & Merrill, 1986; Merrill, 1990; Otero & Merrill, 1994; Hanisch & Quirion, 1996) and neurons (Sarder, Saito, & Abe, 1993; Shimojo, Imai, Nakajima, Mizushima, Uemura, & Kohsaka, 1993; Hanisch & Quirion, 1996) , IL-2 possesses many neuromodulatory properties also. The neuromodulatory effects of IL-2 in vitro include modulation of potassium-evoked acetylcholine release from hippocampal and cortical slices (Araujo, Lapchak, Collier, & Quirion, 1989; Hanisch, Seto, & Quirion, 1993) , decreases in potassium-evoked noradrenaline release from hypothalamic slices (Lapchak & Araujo, 1993) , inhibition of both short-and long-term potentiation in hippocampal slices (Tancredi, Zona, Velotti, Eusebi, & Santoni, 1990) , depression of calcium currents in hippocampal neurons (Plata-Salaman & ffrench-Mullen, 1993), increases in dopamine release from striatal slices (Lapchak, 1992) , modulation of potassium, N-methyl-D-aspartate (NMDA), and kainateevoked dopamine release from mesencephalic neurons (Alonso, Chaudieu, Diorio, Krishnamurthy, Quirion, & Boksa, 1993) , and control of the production of some anterior pituitary hormones (Karanth & McCann, 1991) . When injected into different
